CLINICAL_TRIALS
trial_result
· 2017-02-01
Clinical Trial Update: Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patient With Chronic HBV [Phase 3]
Summary
Phase 3 safety and antiviral activity study of clevudine 30 mg once daily in patients with chronic hepatitis B. The trial status is terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bukwang Pharmaceutical | Conditions: Hepatitis B | Phase 3 | Status: TERMINATED